Corticosteroids and second-line immunosuppressants for immune-related adverse events and melanoma survival

RJ Verheijden; JC Janssen; AE Putker; SPGR Veenstra; GAP Hospers; MJB Aarts; KW Hehenkamp; VLE Doornebosch; M Verhaert; FWPJ Van den Berkmortel; FH Burgers; JBAG Haanen; D Piersma; E Kapiteijn; M Labots; MJ Boers-Sonderen; AAM Van der Veldt; S Aspeslagh; AM May; KPM Suijkerbuijk

doi:10.1016/j.annonc.2023.09.2291

Corticosteroids and second-line immunosuppressants for immune-related adverse events and melanoma survival

RJ Verheijden, JC Janssen, AE Putker, SPGR Veenstra, GAP Hospers, MJB Aarts, KW Hehenkamp, VLE Doornebosch, M Verhaert, FWPJ Van den Berkmortel, FH Burgers, JBAG Haanen, D Piersma, E Kapiteijn, M Labots, MJ Boers-Sonderen, AAM Van der Veldt, S Aspeslagh, AM May, KPM Suijkerbuijk

Research output: Contribution to journal › Meeting abstract (Journal)

Original language	English
Pages (from-to)	S690-S691
Number of pages	2
Journal	Annals of Oncology
Volume	34
DOIs	https://doi.org/10.1016/j.annonc.2023.09.2291
Publication status	Published - Oct 2023
Event	ESMO Immuno-oncology 2023 - Geneva, Switzerland Duration: 6 Dec 2023 → 8 Dec 2023

Access to Document

10.1016/j.annonc.2023.09.2291

Handle.net

Persistent link

Cite this

Verheijden, RJ., Janssen, JC., Putker, AE., Veenstra, SPGR., Hospers, GAP., Aarts, MJB., Hehenkamp, KW., Doornebosch, VLE., Verhaert, M., Van den Berkmortel, FWPJ., Burgers, FH., Haanen, JBAG., Piersma, D., Kapiteijn, E., Labots, M., Boers-Sonderen, MJ., Van der Veldt, AAM., Aspeslagh, S., May, AM., & Suijkerbuijk, KPM. (2023). Corticosteroids and second-line immunosuppressants for immune-related adverse events and melanoma survival. Annals of Oncology, 34, S690-S691. https://doi.org/10.1016/j.annonc.2023.09.2291

@article{5ba8a5cf05094f6ba6a36698ffaef785,

title = "Corticosteroids and second-line immunosuppressants for immune-related adverse events and melanoma survival",

author = "RJ Verheijden and JC Janssen and AE Putker and SPGR Veenstra and GAP Hospers and MJB Aarts and KW Hehenkamp and VLE Doornebosch and M Verhaert and {Van den Berkmortel}, FWPJ and FH Burgers and JBAG Haanen and D Piersma and E Kapiteijn and M Labots and MJ Boers-Sonderen and {Van der Veldt}, AAM and S Aspeslagh and AM May and KPM Suijkerbuijk",

year = "2023",

month = oct,

doi = "10.1016/j.annonc.2023.09.2291",

language = "English",

volume = "34",

pages = "S690--S691",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

note = "ESMO Immuno-oncology 2023 ; Conference date: 06-12-2023 Through 08-12-2023",

}

Verheijden, RJ, Janssen, JC, Putker, AE, Veenstra, SPGR, Hospers, GAP, Aarts, MJB, Hehenkamp, KW, Doornebosch, VLE, Verhaert, M, Van den Berkmortel, FWPJ, Burgers, FH, Haanen, JBAG, Piersma, D, Kapiteijn, E, Labots, M, Boers-Sonderen, MJ, Van der Veldt, AAM, Aspeslagh, S, May, AM & Suijkerbuijk, KPM 2023, 'Corticosteroids and second-line immunosuppressants for immune-related adverse events and melanoma survival', Annals of Oncology, vol. 34, pp. S690-S691. https://doi.org/10.1016/j.annonc.2023.09.2291

TY - JOUR

T1 - Corticosteroids and second-line immunosuppressants for immune-related adverse events and melanoma survival

AU - Verheijden, RJ

AU - Janssen, JC

AU - Putker, AE

AU - Veenstra, SPGR

AU - Hospers, GAP

AU - Aarts, MJB

AU - Hehenkamp, KW

AU - Doornebosch, VLE

AU - Verhaert, M

AU - Van den Berkmortel, FWPJ

AU - Burgers, FH

AU - Haanen, JBAG

AU - Piersma, D

AU - Kapiteijn, E

AU - Labots, M

AU - Boers-Sonderen, MJ

AU - Van der Veldt, AAM

AU - Aspeslagh, S

AU - May, AM

AU - Suijkerbuijk, KPM

PY - 2023/10

Y1 - 2023/10

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=myvubstarterapi&SrcAuth=WosAPI&KeyUT=WOS:001087480201488&DestLinkType=FullRecord&DestApp=WOS_CPL

U2 - 10.1016/j.annonc.2023.09.2291

DO - 10.1016/j.annonc.2023.09.2291

M3 - Meeting abstract (Journal)

SN - 0923-7534

VL - 34

SP - S690-S691

JO - Annals of Oncology

JF - Annals of Oncology

T2 - ESMO Immuno-oncology 2023

Y2 - 6 December 2023 through 8 December 2023

ER -

Corticosteroids and second-line immunosuppressants for immune-related adverse events and melanoma survival

Access to Document

Handle.net

Other files and links

Cite this